Bristol Myers, J&J’s next-gen blood thinner fails key trial in another setback for factor XI

Pharma’s big quest to make safer blood thinners isn't going well. On Friday, Bristol Myers Squibb and Johnson & Johnson announced that a Phase 3 trial of their experimental drug milvexian ...